Revolution Medicines, Inc.
RVMD
$37.01
$0.531.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -90.70% | 9.39% | |||
| Gross Profit | 90.70% | -9.39% | |||
| SG&A Expenses | 15.91% | 24.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.95% | 11.30% | |||
| Operating Income | -9.95% | -11.30% | |||
| Income Before Tax | -16.11% | -9.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.11% | -9.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.11% | -9.69% | |||
| EBIT | -9.95% | -11.30% | |||
| EBITDA | -9.95% | -11.41% | |||
| EPS Basic | -15.83% | -1.29% | |||
| Normalized Basic EPS | -15.84% | -0.90% | |||
| EPS Diluted | -15.83% | -1.29% | |||
| Normalized Diluted EPS | -15.84% | -0.90% | |||
| Average Basic Shares Outstanding | 0.23% | 8.28% | |||
| Average Diluted Shares Outstanding | 0.23% | 8.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||